• Specialty
  • Cardiology
  • Dentistry
  • Dermatology
  • General Medicine
  • GI/GU
  • Hematology
  • Immunology
  • Lab Medicine & Pathology
  • Neuro-Psych
  • OB-Gyn
  • Oncology
  • Ophthalmology
  • Orthopaedic
  • Otolaryngology - ENT
  • Radiology
  • Surgery

• Oncology
  • Lots of Radiology/Oncology Terms
  • Cancer Classification
  • Cancer Drugs
  • Cancer Terms
  • Chemotherapy Treatments
  • Sample Reports - Hematology - Oncology

• Cancer Drugs

- Y -

• yttrium Y 90 DOTA monoclonal antibody HuAFP31

A radioimmunoconjugate comprised of the monoclonal antibody HuAFP31, directed against alpha fetoprotein, that is conjugated to the chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope Yttrium Y90. Yttrium Y 90 DOTA monoclonal antibody HuAFP31 binds to tumor cells expressing alpha fetoprotein, selectively delivering a cytotoxic dose of beta radiation.



• yttrium Y 90 DOTA monoclonal antibody HuPAM4

A radioimmunoconjugate comprised of the humanized monoclonal antibody HuPAM4, directed against the pancreatic cancer antigen MUC1, that is conjugated to the chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope Yttrium Y90. Yttrium Y 90 DOTA monoclonal antibody HuPAM4 binds to tumor cells expressing MUC1 antigen, selectively delivering a cytotoxic dose of beta radiation.



• yttrium Y 90 glass microspheres

An injectable formulation of yttrium Y 90 consisting of glass microspheres containing the radioisotope yttrium Y 90. When injected into the tumor vascular bed, yttrium Y 90 glass microspheres occlude tumor blood vessels and deliver a cytotoxic dose of beta radiation to the tumor site, thereby reducing the tumor burden.



• yttrium Y 90 humanized epratuzumab

A radioimmunotherapeutic humanized murine monoclonal antibody (LL2) directed against the CD22 pan-B-cell antigen and chelated to the radioisotope yttrium-90 (Y 90). Y 90 humanized monoclonal antibody LL2 binds to tumor cells expressing CD222, delivering a cytotoxic dose of beta radiation.



• yttrium Y 90 ibritumomab tiuxetan

A radioimmunotherapeutic agent consisting of a murine monoclonal anti-CD20 antibody (ibritumomab) linked by the chelator tiuxetan to the radioisotope yttrium-90 (Y 90). Yttrium Y 90 ibritumomab tiuxetan binds to and specifically delivers beta radiation to CD20-expressing tumor cells, thereby minimizing the systemic effects of radiation.



• yttrium Y 90 monoclonal antibody BrE-3

A radioimmunotherapeutic agent consisting of a monoclonal antibody (BrE-3) directed against the tumor-associated antigen epithelial glycoprotein mucin chelated to the radioisotope yttrium-90. Yttrium Y 90 monoclonal antibody BrE-3 binds to tumor cells expressing epithelial glycoprotein mucin, selectively delivering a cytotoxic dose of beta radiation.



• yttrium Y 90 monoclonal antibody Hu3S193

A radioimmunotherapeutic agent consisting of a humanized murine monoclonal antibody (hu3S193) directed against the tumor-associated Lewis Y epithelial antigen chelated to the radioisotope yttrium-90. Yttrium Y 90 monoclonal antibody Hu3S193 binds to Lewis Y epithelial antigen-expressing tumor cells, selectively delivering a cytotoxic dose of beta radiation.



• yttrium Y 90 monoclonal antibody MN-14

A radioimmunotherapeutic monoclonal antibody (MN-14) directed against tumor-associated carcinoembryonic antigen (CEA) and chelated to the radioisotope yttrium-90 (Y 90). Y 90 monoclonal antibody MN-14 binds to tumor cell expressing CEA, delivering a cytotoxic dose of beta radiation.



• yttrium Y 90-DOTA-chimeric monoclonal antibody cG250

A radioimmunoconjugate comprised of the chimeric monoclonal antibody cG250 conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and lableled with the beta-emitting radioisotope yttrium Y 90. The antibody moiety of yttrium Y 90 DOTA chimeric monoclonal antibody cG250 binds to renal cell carcinoma cells expressing the G250 antigen, thereby selectively delivering a cytotoxic dose of beta radiation.



• yttrium Y 90-DOTA-tyr3-octreotide

A radiotherapeutic agent consisting of an analogue of the octapeptide octreotide (SMT 487) chelated to the radioisotope yttrium-90. Yttrium Y 90-DOTA-tyr3-octreotide binds to somatostatin receptor-expressing tumor cells, selectively delivering a cytotoxic dose of beta radiation.